Antipodes Partners’s Tarsus Pharmaceuticals TARS Stock Holding History

Antipodes Partners’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-555	Closed	-$38.9K	–	151
2026 Q1	$38.9K	Buy	+555	New	+$38.8K	﹤0.01%	109

Other funds holding TARS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Antipodes Partners's TARS Position: Q2 2026 in Review

Antipodes Partners sold out of Tarsus Pharmaceuticals (TARS) in Q2 2026, closing a stake of 555 shares — an estimated $38.9K sold.

Antipodes Partners first reported a position in TARS in Q1 2026 and held it in 1 quarter. The position peaked at $38.9K in Q1 2026. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

Antipodes Partners reported no remaining Tarsus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Antipodes Partners sold 555 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $38.9K.
Antipodes Partners first reported a position in Tarsus Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Antipodes Partners's Tarsus Pharmaceuticals position peaked at $38.9K in Q1 2026.
257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Antipodes Partners's 13F filing for Q2 2026, filed 6 Aug 2026.